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IMPORTANCE Preschool vision screening could allow detection and treatment of vision
abnormalities during a critical developmental stage, preserving function and quality of life.
OBJECTIVE To review the evidence on screening for and treatment of amblyopia, its risk
factors, and refractive error in children aged 6months to 5 years to inform the US Preventive
Services Task Force.
DATA SOURCES MEDLINE, Cochrane Library, CINAHL, and trial registries through June 2016;
references; and experts, with surveillance of the literature through June 7, 2017.
STUDY SELECTION English-language randomized clinical trials (RCTs) or prospective cohort
studies that evaluated screening, studies evaluating test accuracy, RCTs of treatment vs
inactive controls, and cohort studies or case-control studies assessing harms.
DATA EXTRACTION AND SYNTHESIS Dual review of abstracts, full-text articles, and study
quality; qualitative synthesis of findings. Studies were not quantitatively pooled because of
clinical andmethodological heterogeneity.
MAIN OUTCOMES ANDMEASURES Visual acuity, amblyopia, school performance, functioning,
quality of life, test accuracy, testability, and harms.
RESULTS Forty studies were included (N = 34 709); 34 evaluated test accuracy. No RCTs
compared screening with no screening, and no studies evaluated school performance,
function, or quality of life. Studies directly assessing earlier or more intensive screening were
limited by high attrition. Positive likelihood ratios were between 5 and 10 for amblyopia risk
factors or nonamblyogenic refractive error in most studies of test accuracy and were greater
than 10 in most studies evaluating combinations of clinical tests. Inability to cooperate may
limit use of some tests in children younger than 3 years. Studies with low prevalence (<10%)
of vision abnormalities showed high false-positive rates (usually >75%). Among children with
amblyopia risk factors (eg, strabismus or anisometropia), patching improved visual acuity of
the amblyopic eye by amean of less than 1 line on a standard chart after 5 to 12 weeks for
children pretreated with glasses (2 RCTs, 240 participants); more children treated with
patching than with no patching experienced improvement of at least 2 lines (45% vs 21%;
P = .003; 1 RCT, 180 participants). Patching plus glasses improved visual acuity by about 1 line
after 1 year (0.11 logMAR [95% CI, 0.05-0.17]) for children not pretreated with glasses (1 RCT,
177 participants). Glasses alone improved visual acuity by less than 1 line after 1 year (0.08
logMAR [95% CI, 0.02-0.15], 1 RCT, 177 participants).
CONCLUSIONS AND RELEVANCE Studies directly evaluating the effectiveness of screening
were limited and do not establish whether vision screening in preschool children is better
than no screening. Indirect evidence supports the utility of multiple screening tests for
identifying preschool children at higher risk for vision problems and the effectiveness of some
treatments for improving visual acuity outcomes.
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T he most common causes of vision problems in childrenare amblyopia (a neurodevelopmental disorder thatarises from abnormal processing of visual images that
leads to a functional reduction of visual acuity) and its associated
risk factors (Table 1), nonamblyopic strabismus and nonamblyo-
pic refractive error.9-12 Recent prevalence estimates of amblyopia,
strabismus, and anisometropia (a difference in refractive power
between the eyes, in which one foveal image is more blurred than
the other) among US children younger than 6 years range from
1% to 6%.12-16
Avarietyof vision screening tools are available to evaluate chil-
dren (Table 2). Left untreated, vision abnormalities in young chil-
dren could lead to problems at school, bullying, reduced function
and quality of life, depression and anxiety, and injuries. Vision ab-
normalities are often treatable, but efficacy can decrease as chil-
drenage,andvisual losscanbecomeirreversible.20-24Untreatedam-
blyopia rarely resolves spontaneously.25,26
In 2011, the US Preventive Services Task Force (USPSTF) rec-
ommended screening children to detect amblyopia or its risk fac-
tors at least once between the ages of 3 to 5 years (B recommen-
dation) and concluded that the evidence was insufficient to
assess the balance of benefits and harms of vision screening for
children younger than 3 years (I statement). To inform an updated
recommendation, a review was undertaken of the evidence on
benefits and harms of vision screening in children; screening test
accuracy; and benefits and harms of treatment of amblyopia, its
risk factors, and refractive error.
Methods
Scope of Review
Detailed methods and additional details of results and analyses
are reported in the full evidence report available at https://www
.uspreventiveservicestaskforce.org/Page/Document/final-evidence
-review/vision-in-children-ages-6-months-to-5-years-screening.
Figure 1 shows the analytic framework and key questions (KQs) that
guided the review.
Data Sources and Searches
PubMed/MEDLINE, the Cochrane Library, and the Cumulative
Index to Nursing and Allied Health Literature (CINAHL) were
searched for English-language articles published from January
2009 through June 2016. Search strategies are listed in the
eMethods in the Supplement. To identify relevant studies pub-
lished before 2009, all articles included in the 2011 systematic
review for the USPSTF were assessed.28-30 ClinicalTrials.gov
and the World Health Organization International Clinical Trials
Registry platform were searched for unpublished literature. To
supplement electronic searches, the reference lists of pertinent
articles, all studies suggested by reviewers, and comments
received during public commenting periods were reviewed. Since
June 2016, ongoing surveillance was conducted through article
alerts and targeted searches of high-impact journals to identify
major studies published in the interim that may affect the conclu-
sions or understanding of the evidence and therefore the related
USPSTF recommendation. The last surveillance was conducted
on June 7, 2017.
Study Selection
Two investigators independently reviewedtitles, abstracts, and full-
textarticles todetermineeligibilityusingprespecifiedcriteria foreach
KQ (eTable 1 in the Supplement). Disagreements were resolved by
discussion. The review included English-language studies of chil-
dren aged 6months to 5 years conducted in countries categorized
as “very high” on the United Nations Human Development Index.
Only studies rated as good or fair quality were included.
Data Extraction andQuality Assessment
For each included study, 1 investigator extractedpertinent informa-
tion about the populations, tests or treatments, comparators, out-
comes, settings, and designs, and a second investigator reviewed
for completeness and accuracy. To provide a consistent metric for
visual acuity outcome measures, results were converted to loga-
rithm of the minimal angle of resolution (logMAR) measurements
usingestablished conversion charts.31Measuresof visual acuity are
generally reported as Snellen (eg, 20/20, 20/25, 20/30, 20/40,
20/50)or logMARscales (eg,0.00,0.09,0.18,0.30,0.40). Two in-
dependent investigatorsassessedthequalityof studiesasgood, fair,
or poor, using predefined criteria developed by the USPSTF and
adapted for this topic (eTables 2-5 in the Supplement).32 Disagree-
mentswere resolvedbydiscussion. Individual study quality ratings
are reported in the Supplement (eTables 2-5).
Data Synthesis and Analysis
Findings for each question were summarized in tabular and narra-
tive format. Results of test accuracy studies were not quantita-
tively pooled because of considerable clinical and methodological
heterogeneity (eg,different tests, targetconditiondefinitions,popu-
lations, and results), and there were too few treatment trials mak-
ing similar comparisons to attempt quantitative synthesis.
For KQ2, sensitivities, specificities, likelihood ratios (LRs), and
predictive valueswere calculatedwhen articles reported sufficient
data.WhenqualitativelyevaluatingLRs,positiveLRs indicatedamini-
mal (>1-2), small (>2-5), moderate (>5-10), or large (>10) increase in
the risk of the condition of interest (eg, amblyopia or its risk fac-
tors). Negative LRs indicated a minimal (0.5-<1), small (0.2-<0.5),
moderate (0.1-<0.2), or large (<0.1) decrease in the risk of the con-
dition of interest. Likelihood ratios less than 0.1 or greater than 10
provide strong evidence for ruling out (negative LR <0.1) or ruling
in (positive LR >10) diagnoses.33,34
Definitions for what constitutes a minimal clinically important
change in visual acuity in young children vary across studies.
Recent studies consider a change of 0.2 logMAR (about 2 lines on
the Snellen chart) the minimal clinically important change.35-39
Others consider smaller changes clinically meaningful, generally
between 0.10 logMAR (about 1 line on the Snellen chart) and
0.15 logMAR (between 1 and 2 lines).40-42 Large treatment stud-
ies have calculated sample size requirements based on the ability
to detect a change of at least 0.1 logMAR between treatment
groups.43-46 When assessing whether improvement in visual acu-
ity represents a clinically meaningful change, practitioners may
also consider that visual impairment associated with amblyopia
can become permanent and may limit function for the child’s
lifetime.23,47
The overall strength of the body of evidence was assessed for
each KQ as high, moderate, low, or insufficient using methods
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developed for the USPSTF (and the Evidence-based Practice Cen-
ter program29,30), based on the overall quality of studies, consis-
tency of results between studies, precision of findings, and risk of
reporting bias.
Results
A total of 40 published studies (described in 46 articles40,44,48-91)
with 34 709 participants were included (Figure 2). The main re-
sults for each KQ are summarized below.
Benefits of Screening
Key Question 1. Does screening for amblyopia, its risk factors, and
refractive error in children aged 6 months to 5 years reduce long-
termamblyopiaor improvevisual acuity, school performance, func-
tioning, and/or quality of life?
KeyQuestion1a.Doestheeffectivenessofscreening inchildrenaged
6months to 5 years vary among different age groups?
One randomized clinical trial (RCT)86,89 and 1 cohort study90
enrolling children from theAvon Longitudinal Study of Parents and
Children(ALSPAC)projectwere included(Table3).TheALSPACproj-
ect is a geographically defined birth cohort study enrolling 14000
Table 1. Risk Factors for Amblyopiaa,b
Risk Factorc
Age, mo
12-30 31-48 >48
Astigmatism, diopters >2.0 >2.0 >1.5
Hyperopia, diopters >4.5 >4.0 >3.5
Anisometropia, diopters >2.5 >2.0 >1.5
Myopia, diopters >−3.5 >−3.0 >−1.5
Manifest strabismus in primary position, prism diopters >8 >8 >8
Media opacity, mm >1 >1 >1
a Adapted fromDonahue et al.1
b Amblyopia is a neurodevelopmental disorder that arises from abnormal
processing of visual images that leads to a functional reduction of visual
acuity.2 It results from conditions that interfere with normal binocular vision.
Specific conditions associated with amblyopia are anisometropia (a difference
in refractive power between the eyes, in which one foveal image is more
blurred than the other), strabismus (ocular misalignment, in which each eye
does not have the same image on the fovea), and deprivation (caused by the
blockage of the visual pathway, often attributable to cataracts, ptosis, or
refractive error due tomyopia, hyperopia, and/or astigmatism).3-7 Strabismic
and anisometropic amblyopia can coexist. Strabismus can also inhibit
development of normal binocular vision in the absence of amblyopia.8
c Ptosis has been removed from the list because nearly all amblyopia-related
ptosis occurs in the setting of superimposed anisometropia.1
Table 2. Screening Tests for Visual Impairment Used in or Available in Primary Care Settings
Category Screening Test Description of Test
Visual acuity test Picture identification tests (eg, LEA Symbols) Figure identification from various distances (eg, the LEA Symbols test uses
a circle, apple, square, and house; symbols gradually decrease in size)
Visual acuity test HOTV eye test Identification of letters HOTV; letters gradually decrease in size
Visual acuity test Snellen Letter or number identification; letters or numbers gradually decrease in size
Visual acuity test Tumbling E Identification of the direction of arms of the letter E; letters gradually
decrease in size
Stereoacuity test Contour stereotests (eg, Frisby, Random Dot E,
Randot Stereo Smile, Titmus Fly)
Use of polarized glasses and stereo cards to determine whether a child can
correctly identify a 3-dimensional image
Stereoacuity test Moving dynamic random dot stereosize test17 Computer-generated moving stereotest dots
Ocular alignment test Corneal light reflex test
(Hirschberg testing)
Symmetric light reflex in both pupils from light held 2 feet away; can also
detect cataracts and tumors
Ocular alignment test Cover-uncover test (cross cover test) Alignment changes when covering or uncovering a single focusing eye
Ocular alignment test Simultaneous red reflex test
(Bruckner test)
Equal red reflexes when viewed through ophthalmoscope; can also detect
cataracts and tumors
Photoscreening (multiple
categories)
Photoscreeninga A trained observer evaluates images of corneal light reflexes from a
calibrated camera; binocular; can assess ocular alignment, media opacity,
and visual acuity
Autorefraction (automated
visual acuity test)
Autorefractive screeningb Estimates refractive error using an automated device; monocular; does not
assess ocular alignment
a Photoscreening devices use optical images (photographs) of the eye’s red
reflex to identify risk factors in both eyes simultaneously. Most
photoscreeners can estimate refractive error, media opacity, and ocular
alignment.18 Interpretation of the image is subjective and based on
preestablished pass/fail criteria; older devices require a trained interpreter, but
newer machines often include computerized interpretation or relay
information to a central reading system. Image acquisition takes a few seconds
and captures images from both eyes at once, making photoscreeners
especially useful for preverbal or developmentally delayed children and
children unable to tolerate longer examinations.18
bAutorefractors are computerized instruments that provide objective refractive
status bymeasuring how light changes as it enters and reflects off the back of
the eye. For patients with reduced visual acuity, it determines the lens power
required to accurately focus light on the retina. Advantages of autorefractors
include ease and time of use, ready availability, and patient tolerance.
Handheld autorefractors require only a few seconds of a child’s attention,
potentially increasing testability rates vs traditional tabletopmodels,
especially among young children.19 A disadvantage of autorefraction is that it
typically measures 1 eye at a time, limiting its ability to detect strabismus
without refractive error.18
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childrenborn in southwestEnglandbetweenApril 1991 andDecem-
ber 1992.86 Both studies reported prevalence of amblyopia at age
7.5 years; neither evaluated school performance, function, or qual-
ity of life outcomes. Themajormethodological shortcoming inboth
studies was high attrition; around half of children did not have re-
sults and were excluded from analyses. In addition, the method of
randomization in the (self-described) RCT was inadequate (based
on last digit of themother’s day of birth).86,89
The RCT (n = 3490) compared intensive orthoptist screening
(clinical examination, age-specific visual acuity testing, and cover-
uncover testing) before age 3 years (at 8, 12, 18, 25, 31, and 37
months) with 1-time orthoptist screening at age 37 months.86,89
Baseline data for amblyopia or amblyopia risk factors were not
reported. Children in both groups were offered “usual care” in
terms of surveillance for visual problems: (1) examination at ages 8
and 18 months by a health visitor (community pediatric nurse),
with referrals if a visual problem was suspected86; and (2) visual
screening at school entry (ages 4-5 years) by a school nurse.89 The
prevalence of amblyopia at 7.5 years was approximately 1% lower in
the intensive screening group than in the control group, but the dif-
ference was statistically significant for only 1 of their 2 definitions of
amblyopia (Table 3).89 Among those who received patching treat-
ment (n = 40 in each group), presence of residual amblyopia at 7.5
years was more likely in the 1-time screening group than in the
intensive-screening group, but the difference was statistically sig-
nificant for only 1 of the 2 amblyopia definitions, and estimates
were imprecise; visual acuity at 7.5 years in the worse eye was bet-
ter in the intensive-screening group than in the 1-time screening
group (Table 3).89
The prospective cohort study (n = 6081 completers) com-
pared orthoptist screening at age 3 years in 1 health districtwith no
preschool screening in 2 other health districts.90 Screening exami-
nationsbytheorthoptistconsistedofamonocularvisiontest,acover
test, andanassessmentof binocularity; failureof anypart of theex-
amination resulted in referral for further evaluation. All children in
the study area were offered vision screening at school entry (ages
4-5years).90Amongparticipantswhoattended theexaminationat
age 7.5 years and were not part of the ALSPAC RCT, no statistically
significantdifferences inamblyopiawereapparentbetweengroups
based on any of the studies’ 3 definitions of amblyopia (Table 3).90
Figure 1. Analytic Framework and Key Questions
Treatment
Children aged 6 months
to 5 years
Screening
Improved visual acuity
Reduced long-term amblyopia
Better school performance
Improved functioning
Improved quality of life
Outcomes
1
2 4
Harms of
screening
3
Harms of
treatment
5
Amblyopia, amblyopia
risk factors,a and
refractive errorb
Key questions
Does screening for amblyopia, its risk factors, and refractive error in children aged 6 months to 5 years reduce long-term amblyopia
or improve visual acuity, school performance, functioning, and/or quality of life?
1
What are the harms of screening for amblyopia, its risk factors, and refractive error in children aged 6 months to 5 years?3
What are the harms of treating amblyopia, its risk factors, and refractive error in children aged 6 months to 5 years?5
What are the accuracy and reliability of screening tests for amblyopia, its risk factors, and refractive error in children
aged 6 months to 5 years?
2
a. Does the effectiveness of screening in children aged 6 months to 5 years vary among different age groups?
a. Do the accuracy and reliability of screening tests for amblyopia, its risk factors, and refractive error vary among different age groups?
a. Does treatment of amblyopia, its risk factors, and refractive error in children aged 6 months to 5 years improve visual acuity?4
b. Does treatment of amblyopia, its risk factors, and refractive error in children aged 6 months to 5 years reduce long-term amblyopia
or improve school performance, functioning, and/or quality of life?
Evidence reviews for the US Preventive Services Task Force (USPSTF) use an
analytic framework to visually display the key questions that the reviewwill
address to allow the USPSTF to evaluate the effectiveness and safety of a
preventive service. The questions are depicted by linkages that relate
interventions and outcomes. Further details are available in the USPSTF
procedure manual.27
a Amblyopia risk factors include anisometropia, strabismus, hyperopia, any
media opacity, astigmatism, and abnormal visual acuity (which includes
substantial isoametropic refractive error).
bDetermination of refractive error is based on age-appropriate standards.
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Accuracy of Screening Tests
KeyQuestion2.What is theaccuracyandreliabilityofscreeningtests
for amblyopia, its risk factors, and refractive error in children aged
6months to 5 years?
Thirty-four fair-quality studies (described in 38 articles) were
included (eTables 6-17 in the Supplement).48,49,51-62,64-85,88,91
The studies evaluated a variety of test types, including visual acu-
ity tests, stereoacuity tests, ocular alignment tests, autorefrac-
tors, photoscreeners, and retinal birefringence scanning. Screen-
ing was administered by a variety of personnel across studies
(eg, pediatricians, ophthalmologists, nurses, research staff).
Sample sizes ranged from 6375 to 4040.70,91
About one-third of the studies included participants younger
than 3 years.48,56,65,66,71,72,75-77,80,81,85,88,91 The included
studies reported accuracy of tests for a variety of target con-
ditions, ranging from very specific (eg, astigmatism) to broad
(eg, amblyopia risk factors). The prevalence of target conditions
was generally much higher in samples from ophthalmology
clinics53,56,57,62,66,68,69,72,75,77,80,81,85,88 than in those from pri-
mary care, community, Head Start, or school settings.
Findings from the Vision In Preschoolers (VIP) study, the larg-
est study for this KQ, were reported in multiple manuscripts
(up to 4040 participants).55,60,64,70,78,82,84,91 Phase 1 of
the VIP study enrolled 3- to 5-year-olds and compared the accu-
racy of 11 screening tests.78 Phase 2 compared the performance
of nurse screeners with that of lay screeners for 4 tests.84
Unlike many of the included studies, the VIP study evaluated
accuracy for a broad range of conditions, including significant
nonamblyogenic refractive error. The applicability of the VIP
study may be limited because it did not enroll a representative
spectrum of patients (as demonstrated by the high prevalence of
target conditions, ranging from 21%-36%), study participants
may have experienced fatigue from the number of tests, and test-
ing was conducted by skilled personnel in a controlled environ-
ment (in phase 1).
Detailed results of studies evaluating test accuracy are pro-
vided in the eResults and eTables 6 through 17 in the Supplement.
Six publications evaluated visual acuity tests,53,73,74,78,82,84
including 3 from the VIP Study Group.78,82,84 When screening test
cutoffs were set to achieve specificities of 90%, phase 1 of the
VIP study found that an abnormal result moderately increased
the likelihood of amblyopia, amblyopia risk factors (strabismus,
astigmatism, hyperopia, myopia, anisometropia), or significant
nonamblyogenic refractive error (positive LR, 6.1 [95% CI,
Figure 2. Summary of Evidence Search and Selection
2069 Unique records identified through
database searching
1851 MEDLINE
175 ClinicalTrials.gov and
WHO ICTRP
41 Cochrane Library
2 CINAHL
113 Additional records identified
through other sources
60 From references from
2011 review
33 Hand searches and references
20 Suggested by peer reviewers
46 Articles (40 studies) included
in systematic review
320 Full-text articles excluded
29 Non-English language
14 Ineligible screening or prevention
70 Ineligible comparator
37 Ineligible outcome
29 Ineligible study design
9 Ineligible country (but met all
other criteria)
6 Poor quality
20 Not original research
106 Ineligible population
1816 Abstracts excluded
3 Articles (2 studies)
included for KQ1a
38 Articles (34 studies)
included for KQ2a
18 Articles (17 studies)
included for KQ3a
3 Articles (3 studies)
included for KQ4a
4 Articles (3 studies)
included for KQ5a
366 Full-text articles assessed
for eligibility
2182 Records screened
CINAHL indicates Cumulative Index to Nursing and Allied Health Literature;
KQ, key question; WHO ICTRP, World Health Organization International Clinical
Trials Registry.
a Sum of the numbers of studies or articles per KQ exceeds the total number of
included studies or articles because somewere included in multiple KQs.
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4.8-7.6]).78 A normal result indicated a small decrease in the likeli-
hood (negative LR, 0.43 [95% CI, 0.38-0.50]).
Four fair-quality studies (total, 1854 participants) evaluated a
combination of clinical tests, including visual acuity tests, stereoa-
cuity tests, and ocular alignment tests (eTables 6-7 in the
Supplement).52,54,67,80 Three of the 4 found that abnormal results
indicated a large increase in the likelihood of amblyopia or its risk
factors (positive LRs ranged from12-17).52,67,80The4 studies found
more variability for negative LRs (range, 0.10-0.91).
S ixteen fa i r-qua l i ty stud ies ( 16 712 observat ions)
evaluated autorefractors (eTables 6-17 in the Supple-
ment).49,51,55,57,58,65,66,70,72-74,77,78,84,88,91 Overall, most studies
found moderate positive LRs and small negative LRs, although
some found large positive and negative LRs.
Eleven fair-quality studies (12 publications, 6187 obser-
vations) evaluated photoscreeners (eTables 6-15 in the
Supplement).56,59,67-69,73,75-78,81,85 Overall, most studies found
moderate positive LRs and small negative LRs, although some
found larger or smaller LRs.
Key Question 2a. Does the accuracy or reliability of screening
tests for amblyopia, its risk factors, and refractive error vary
among different age groups?
Five studies evaluatedwhether accuracy varies by age (eTable
13 in the Supplement).54,66,69,81,82 All 5 evaluated different screen-
ing tests and assessed different age stratifications/comparisons.
Overall, data were limited and estimates were somewhat impre-
cise, but studies did not find any clear differences in test accuracy
when results were stratified by age.
Many included studies reported testability information,
although few reported data stratified by age or for children
younger than 3 years. eTable 14 in the Supplement details
the proportion unexaminable reported by studies. Overall, test-
ability exceeded 90% in the majority of studies. Few studies
reported testability rates less than 80%, but all that did included
children younger than 3 years.48,66,71,77 Some studies demon-
strated that testability rates improved somewhat as children
age.53,66,71,77,78,80 One study (n = 1170) found that testability
rates were 10% for a visual acuity test at ages 24 months to
younger than 30 months and steadily improved to 80% by ages
36 months to younger than 42 months and to 95% by ages 48
months to younger than 54 months.71
Forautorefractorsandphotoscreeners, theVIPstudyfoundtest-
ability rates close to 100%(all participantswere3years or older).78
Two studies from ophthalmology clinics and 1 from a primary care
practice reportedbetter testability forolderpreschool children than
for younger ones (eResults in the Supplement).65,66,77
Harms of Screening
KeyQuestion 3.What are the harmsof screening for amblyopia, its
risk factors, andrefractiveerror inchildrenaged6months to5years?
One controlled study that evaluated potential psycho-
social effects was included,87 and 16 studies of test accuracy
described in KQ2 were used to calculate false-posit ive
rates.48,51,52,55,62,65,67,69,75-78,80-82,85 The controlled study used
the ALSPAC population-based cohort (n = 4473) to assess bully-
ing by age 8 years.87 It prospectively compared children who had
been offered state-provided preschool screening for amblyopia
(at 37 months) with those who had not. Children were asked
whether they had repeatedly (4 times a month) been bullied.
Among the subgroup of patched children, the study showed a
lower likelihood of being bullied for children offered screening
than for those not offered early screening (25.7% vs 47.1%,
P = .033; adjusted odds ratio, 0.39 [95% CI, 0.16-0.92], adjusted
for sex, paternal socioeconomic class, highest level of maternal
education, type of housing).
Themost frequentlyassessedpotentialharmsofscreeningwere
false-positive findings (which would lead to unnecessary refer-
rals). Ingeneral, studieswitha lowerprevalence (<10%)ofvisionab-
normalities showedmuchhigher false-positive rates (usually >75%),
while those with a high prevalence had lower false-positive rates
(usually <35%) (eFigure in the Supplement).
Benefits of Treatment
Key Question 4a. Does treatment of amblyopia, its risk factors,
and refractive error in children ages 6 months to 5 years improve
visual acuity?
KeyQuestion4b.Does treatmentof amblyopia, its risk factors, and
refractive error in children ages 6 months to 5 years reduce long-
termamblyopiaor improveschoolperformance, functioning, and/or
quality of life?
Three trials were included (Table 4)40,44,50; all evaluated
patching for amblyopia or amblyopic risk factors. Two compared
patching with no patching (children were pretreated with eye-
glasses if indicated in both groups),44,50 and 1 compared patching
plus eyeglasses vs eyeglasses alone vs no treatment.40 One of the
patching vs no patching trials included a run-in phase, during
which all participants wore updated eyeglass prescriptions until
visual acuity in the amblyopic eye stopped improving44; another
trial treated children with refractive error with 6 weeks of correc-
tive lenses before allocation.50 All 3 studies included children
based on visual acuity criteria. One of the 3 trials reported enroll-
ing screen-detected children.40 Two of the trials reported best
corrected visual acuity,40,44 and 1 measured improvement in
visual acuity as a secondary outcome (the trial focused primarily
on assessing adherence).50
Overall, the trials indicated that treatments for amblyopiaor its
risk factors resulted in small mean improvements in visual acuity
(Table 4). In the study with the run-in phase,44 patching improved
visual acuity by a mean of 0.7 of a line on a standard visual acuity
chart, andmore children treatedwith patching thanwith nopatch-
ing had at least 2 lines of improvement in acuity (45% vs 21%).
Two included trials40,44 examined treatment outcomes for
subgroups defined by baseline visual acuity. First, 1 trial (n = 180)
assessed subgroups with either moderate (20/40 to 20/100) or
severe (20/125 to 20/400) amblyopia at baseline.44 Findings for
these subgroups were similar to the overall trial results for the pri-
mary outcome, visual acuity in the amblyopic eye. Second, the
trial that compared patching plus eyeglasses, eyeglasses alone,
and no treatment among preschoolers (n = 177) assessed sub-
groups defined by baseline visual acuity abnormalities.40 The
authors assessed children with mild (0.18-0.30 logMAR) and
moderate or worse (0.48 logMAR) refractive error at baseline
and examined differences between treatment groups. For chil-
dren with moderate refractive error at baseline, patching plus
eyeglasses resulted in much greater improvement than no treat-
ment at 1 year (0.27 logMAR [95% CI, 0.14-0.39], compared with
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improvement for all participants of 0.11 logMAR [95% CI, 0.05-
0.17]); the difference between eyeglasses alone and no treatment
did not reach statistical significance. For children with mild refrac-
tive error at baseline, neither treatment was significantly different
than no treatment at the end of the trial.
Harms of Treatment
KeyQuestion 5.What are the harms of treatment of amblyopia, its
risk factors, andrefractiveerror inchildrenaged6months to5years?
Three trials (described in 4 articles) were included
(Table4).40,44,50,63Overall, the trials provided limitedevidencebut
suggest that patchingmay have some psychological harms.
One trial comparingpatchingwithnopatching (n = 180) found
that worsening visual acuity in the nonamblyopic eye was not sig-
nificantly different between groups at 5 weeks (2.4% vs 6.8%, re-
spectively; P = .28).44 Among children with no ocular deviation at
baseline (n = 118), 5 patients in the patching group and 3 patients
in theno-patchinggroupwerenoted tohaveanewsmall-angle stra-
bismus, and 1 patient in the no-patching groupwas noted to have a
new large-angle strabismus.
The trial comparingpatchingpluseyeglasses, eyeglasses alone,
and no treatment found no statistically significant difference be-
tweentreatmentgroupsat 1-year follow-up in theproportionof chil-
dren whose uncorrected visual acuity in the amblyopic eye wors-
ened (change >0.1 logMAR) for thosewith baselinemild acuity loss
(9.7%vs6.5%vs 13.3%, respectively,P = .28)or for thosewithbase-
line moderate acuity loss (15.0% vs 11.1% vs 23.8%, P = .13).40
A substudy63 of the trial40 that compared patching plus eye-
glasses, eyeglasses alone, and no treatment examined the emo-
tional status of children undergoing treatment; in the substudy,
144 of 177 parents of participants completed questionnaires at
baseline (all participants), 3 months after beginning treatment
(participants in active treatment only), and 2 years after recruit-
ment (all participants). They found no significant differences
between treatment groups with regard to being happy, coopera-
tive, or good tempered; teasing; problems at preschool; or in
emotional and behavioral problems, but found that children were
more upset by patching plus eyeglasses than by eyeglasses alone
(85% vs 29% at age 4 years, P = .03; 62% vs 26% at age 5 years,
P = .005). Although the study reported some negative effects of
glasses or patching for the child (difficulty wearing patch or
glasses, upset, coping with treatment) and parent (worry about
treatment, upset by treatments, arguments about treatment), it
did not report a comparison with the no-treatment group for
these outcomes.
One trial (n = 60)comparingnotreatment,patching for3hours
daily, or patching for 6 hours daily reported that no patients expe-
rienced an adverse event, such as inverse amblyopia or patch
allergy.50
Discussion
The summary of findings is presented in Table 5. No eligible RCTs
directly compared screening with no screening. For the overarch-
ing question (KQ1), the strength of evidencewas graded as low be-
causeofunknownconsistency(withasinglestudymakingeachcom-
parison), imprecision, and methodological limitations. One cohort
study showed a reduction in harm (ie, less school-aged bullying)
among patched children screened in preschool compared with
patched children not screened in preschool.87 In theory, although
both glasses and patching have been reported to increase the risk
of beingbullied,92preschool screeningmayallow for treatmentbe-
fore school starts, thus avoiding potential bullying and psychoso-
cial distress.
Harms of preschool vision screening might include unneces-
sary referrals from false-positive screens, overdiagnosis, and un-
necessary treatment. Studies of test accuracy show that screening
tests are associated with high false-positive rates among popula-
tions with a low prevalence of vision abnormalities. A large
(n = 102 508) retrospective study from a statewide photoscreen-
ing program found that 19.5% (174/890) of those with false-
positive test results were prescribed glasses (ie, unnecessary
treatments).93 The study was not eligible for this systematic re-
view because it did not attempt to perform the reference standard
in all participants or a random sample of participants.
Regarding testaccuracy,estimates forall tests suggestutility for
identifying childrenat higher risk for amblyopia risk factors or other
visual conditions. Positive LRs were in the moderate range (>5-10)
for most studies, andmost studies that evaluated combinations of
clinical tests found high (>10) positive LRs. The VIP study, the larg-
est todirectly comparemultiple tests, generally found similar accu-
racy across tests. The strength of evidence was graded as low, be-
causeof imprecisionandmethodological limitationsof the individual
studies. Findings are applicable to a variety of settings and screen-
ing personnel.
Accuracy did not clearly differ for preschool children in differ-
ent age groups. However, unlike studies of photoscreeners, most
studies of clinical test accuracy did not enroll children younger
than 3 years. Data were relatively limited and estimates were
somewhat imprecise, but studies did not find any clear differ-
ences in accuracy of tests when results were stratified according
to age. Testability may limit the utility of some screening tests,
especially clinical tests, in children younger than 3 years. Although
relatively few studies assessed changes in testability by age,
those that did generally found better testability in children 3 years
or older, and some reported low testability rates for visual acuity
and stereoacuity tests for those younger than 3 years. In contrast,
some data suggest that photoscreeners have high testability rates
for children as young as 1 year.94
The review found evidence of moderate strength supporting
the effectiveness of some treatments for improving visual acuity
outcomes, although mean improvements were small. No studies
evaluated potential effectiveness of treatments for reducing long-
term amblyopia or for improving school performance, function-
ing, or quality of life, and no eligible studies evaluated atropine or
vision therapy. The included trials all enrolled children 3 years or
older, and applicability to those younger than 3 years is unclear.
The trials varied somewhat in the populations (with amblyopic
risk factors and pretreated with glasses or with amblyopic risk fac-
tors but not pretreated with glasses) and interventions compared
(2 evaluated patching vs no patching; 1 compared patching plus
glasses vs glasses alone vs no treatment). The trial that compared
patching plus eyeglasses, eyeglasses alone, and no treatment
enrolled screen-detected children, demonstrating the applicabil-
ity of findings to the main population of interest for this review.40
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Taken together, the treatment trials provide evidence ofmod-
erate strength that (1) patching improves visual acuity of the am-
blyopic eye by ameanof less than 1 line on an eye chart after 5 to 12
weeks comparedwith no patching for childrenwith amblyopic risk
factors pretreatedwith glasses, (2) patching plus glasses improves
visual acuity by about 1 line after 1 year compared with no treat-
ment for children with amblyopic risk factors not pretreated with
glasses, and (3)glassesalone improvevisual acuityby less than 1 line
after 1 year comparedwith no treatment for childrenwith amblyo-
pic risk factors. The magnitude of improvement for patching plus
glasses or glasses alone was greater for those with worse baseline
visual acuity. Few of the trials reported binary outcomes that may
help determine howmany participants achieved a clinically mean-
ingful change, although 1 trial reported that more children treated
with patching than with no patching experienced improvement of
at least 2 lines.44
The review has several limitations. First, for studies of test
accuracy conducted in ophthalmology settings, details about the
study participants were sometimes limited, making it difficult to
determine whether participants had known impaired visual acuity
or obvious symptoms of impaired visual acuity. Thus, the review
may have included some studies that would not meet eligibility cri-
teria if additional description of the study populations was avail-
able. Second, the review did not include comparative effectiveness
(ie, head-to-head) studies, such as those comparing atropine with
patching. The previous review for the USPSTF described head-to-
head trials that compared different patching regimens (eg, 2-hour
vs 6-hour patching), different atropine regimens (daily atropine vs
weekend atropine), and patching with atropine.43,45,46,95-97 It con-
cluded that the trials found no differences in visual acuity improve-
ment in the amblyopic eye between the treatments. Third, studies
published in languages other than English and those conducted in
countries not categorized as very high on the Human Development
Index were excluded.
Conclusions
Studies directly evaluating the effectiveness of screening were lim-
ited and do not establish whether vision screening in preschool
children is better than no screening. Indirect evidence supports the
utility of multiple screening tests for identifying preschool children
at higher risk for vision problems and the effectiveness of some
treatments for improving visual acuity outcomes.
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